Literature DB >> 2863446

Uridine monophosphate kinase 3: a genetic marker for susceptibility to Haemophilus influenzae type B disease.

G M Petersen, D R Silimperi, E M Scott, D B Hall, J I Rotter, J I Ward.   

Abstract

Alaskan Eskimos have the highest known prevalence of invasive Haemophilus influenzae type b (Hib) disease, primarily meningitis, affecting 1-5% of all children in the first two years of life. In this population a polymorphic genetic variant of the pyrimidine pathway enzyme, uridine monophosphate kinase-3 (UMPK-3), was found to be positively associated with invasive Hib disease (relative risk 3.3) and a tendency towards a younger age at onset of illness. There was no difference in levels of naturally acquired Hib anticapsular antibody between persons with Hib disease and healthy controls in this population. This suggests that UMPK-3 may have a role in mediating non-humoral immunity to Hib. However, unlike other enzyme variants in the nucleoside synthesis pathways which result in syndromes of severe immunodeficiency, this gene appears to confer a more subtle disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863446     DOI: 10.1016/s0140-6736(85)92738-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  Cloning, expression in Escherichia coli, and characterization of Arabidopsis thaliana UMP/CMP kinase.

Authors:  L Zhou; F Lacroute; R Thornburg
Journal:  Plant Physiol       Date:  1998-05       Impact factor: 8.340

2.  The epidemiology of Haemophilus influenzae type b disease in the Republic of Ireland.

Authors:  J Fogarty; A C Moloney; J B Newell
Journal:  Epidemiol Infect       Date:  1995-06       Impact factor: 2.451

Review 3.  Chromosome 1 in relation to human disease.

Authors:  S Povey; J M Parrington
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

4.  Class and subclass antibodies to Haemophilus influenzae type b capsule: comparison of invasive disease and natural exposure.

Authors:  K Ramadas; G M Petersen; D C Heiner; J I Ward
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.